3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
18
Triple Negative Breast Neoplasms
16
Carcinoma, Transitional Cell
4
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Salivary Gland Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Urothelial Cancer
1
Meningeal Carcinomatosis
1
Lung Diseases
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
selinexor
1
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Drug Therapy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
sacituzumab govitecan
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled